Navigation Links
Novel gene-silencing nanoparticles shown to inhibit Ewing's sarcoma

A novel delivery system that transports gene silencing nanoparticles into tumor cells has been shown to inhibit Ewing's sarcoma in an animal model of the disease.

In this classic "Trojan horse" approach, a protein called transferrin that normally delivers iron into cells is modified to also smuggle into tumor cells siRNA (short interfering RNA) encased in nano-sized sugar polymers. The siRNA was designed to target a specific growth-promoting gene called EWS-FLI1 that's active only in Ewing's sarcoma tumors.

Once inside these cells, the genetic machinery of the tumor cells are effectively silenced or shut down, preventing further growth.

"This is the first study to show that systemic administration of siRNA can inhibit disseminated tumor growth," said Siwen Hu, a postdoctoral fellow at Children's Hospital of Los Angeles and the University of Southern California, and one of the study's lead investigators.

"We conclude that this novel delivery system is a powerful and simple method to induce gene silencing, with the potential to move to clinical trials," said Hu, who presented the results at the 96th Annual Meeting here of the American Association for Cancer Research.

In recent years, scientists have been intrigued by the potential of siRNA to block the activity of genes that promote the growth of tumors. Harnessing the power of this new technology, however, has proved daunting for a variety of reasons, including the ability to deliver these bits of genetic material in high concentrations to specific tumor sites, while avoiding degradation.

To overcome these hurdles, the scientists employed a sugar-containing polymer invented by chemical engineers at the California Institute of Technology. For this experiment, the polymer binds to and condenses the engineered siRNA into nanoparticles that, in effect, form a protective shield around their precious genetic cargo. These nanoparticles, in turn, are attached to transferrin, a p rotein that typically carries iron molecules through the bloodstream until it meets up with a transferrin receptor on the surface of another cell. The transferrin binds tightly to a receptor on the cell's surface, where it is drawn inside and surrounded by a small vesicle. The vessels are acidified, causing the nanoparticles to release its contents ?the siRNA.

"Since transferrin receptors are upregulated in tumor cells, this delivery system will home in on tumor cells, leaving normal cells in tact," Hu said.

To test their new delivery system, the scientists targeted tumor cells from the patients of Ewing's sarcoma, a rare and often deadly bone cancer that generally strikes young adults. Despite aggressive therapy, about 40 percent of patients with Ewing's family tumors and 95 percent with metastases die as a result of their disease.

Scientists now recognize that Ewing's sarcoma results when two chromosomes break and trade their genetic content in what's technically called a "translocation," activating the oncogene EWS-FLI1 which triggers the tumor growth characteristic for this cancer.

In their experiment, siRNA was delivered to this growth-promoting region of the tumor cell, effectively reducing cell replication by 80 percent.

The scientists then tried their novel technology in laboratory mice grafted with human Ewing's sarcoma tumors. Following three consecutive days of treatment, the scientists observed strong, but transient, inhibition of tumor growth.

However, when used over longer durations (twice-weekly injections up to four weeks), the results were striking.

"Long-term treatments with this delivery system markedly inhibited tumor growth, with little or no tumor growth in many animals," said Hu.

Future experiments will combine the novel delivery system with small molecular anti-tumor agents, with hopes of creating a new and effective way to treat Ewing's sarcoma and other tumors in the clinic.

"Clinically, Ewing's patients are treated with combination of chemotherapeutic agents, but despite aggressive treatments, the patient outcomes are poor," said Hu.

"The delivery system we're developing can shield the drugs from degradation before reaching the target sites, while delivering siRNA for more specificity and potency so as to lower the required dose for efficacy."

The study was a collaborative effort between the laboratory of Timothy J. Triche, at Children's Hospital of Los Angeles; and the laboratory of Mark E. Davis, at the Caltech. Also participating in the study were Jeremy D. Heidel and Derek W. Barlett, both at Caltech.

Support for this research came from the Las Madrinas endowment in Molecular Genetics and Molecular Pathology at the Children's Hospital of Los Angeles, the Whitaker Foundation, with the National Science Foundation funding part of the work at Caltech.


Source:American Association for Cancer Research

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel live reporting system to track cells
10. Field of beams - Novel system uses polarized light pulses to reveal crop health
11. Novel compounds show promise as safer, more potent insecticides
Post Your Comments:

(Date:9/30/2015)... Calif. , Sept. 30, 2015  With nearly ... the number of new SCIs estimated to reach 12,500 ... Southern California Resource Services for Independent Living ... ILCs in California opening doors ... range of programs and services, notably assistive technology services ...
(Date:9/29/2015)... Sept. 29, 2015 News facts: ... while also saving energy , Minimized design shrinks ... Power Active Mode and embedded Fujitsu PalmSecure authentication enable ... Fujitsu today shows that good things come in ... models to its enterprise desktop and mobile portfolio. Featuring ...
(Date:9/28/2015)...  The monitoring of vital signs, such as ... an essential component of patient assessment. Changes in ... a patient,s condition. However, in general care areas ... during routine observation rounds only once every four ... these observation rounds, the warning signs can go ...
Breaking Biology News(10 mins):
... popular with consumers who like the convenience and ... table grapes fresh and increase shelf life, scientists ... alternatives to conventional packing methods. Researchers from the ... ARS) have developed and tested an effective new ...
... OHLoblolly pine bark is the primary component of nursery ... shortage of the widely used organic material is prompting ... recent study by James E. Altland and Charles Krause ... Agricultural Research and Development Center was designed to determine ...
... within patient records or detailed in newspaper clippings can ... the discovery of trends that were previously overlooked, according ... interactive maps and graphs, combined with word search interfaces, ... the spread of Swine flu," said Frank Hardisty, research ...
Cached Biology News:
(Date:10/8/2015)... 2015  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... within its Applied Diagnostics and Testing business segment ... product line with ten certified Snap-N-Spike ® ... and their stable-labeled internal standards. These new solution ... taurocholic acid and native and deuterium-labeled analogs of ...
(Date:10/7/2015)... India , October 8, 2015 /PRNewswire/ ... --> Medical biotechnology accounts for largest ... of bioinformatics in drug discovery and development ... . ... On the basis of applications, the ...
(Date:10/7/2015)... , Oct. 7, 2015  ChromaDex Corp. (OTCQX: ... nutritional ingredients that creates science-based solutions for dietary ... and pharmaceutical products, today announced that the October ... and Founder, is now available for on-demand viewing ... -->   --> ...
(Date:10/7/2015)... RADNOR, Pa. , Oct. 7, 2015   ... global, independent provider of laboratory products, services and ... Technologies Inc. (PTI), a specialty solvent company that ... solvents. This acquisition will enhance VWR,s growing laboratory ... its laboratory and biopharmaceutical manufacturing customers. ...
Breaking Biology Technology:
... JOLLA, Calif., Oct. 20, 2011 Regulus Therapeutics ... development of innovative medicines targeting microRNAs, and collaborators at ... Center today announced the publication of new pre-clinical research ... et al., Nature , October 20, 2011). ...
... cell carcinomas are amongst the most frequent cancers in ... like many other human cancers, contain particular cancer cells, ... potential that sustain tumor growth. Little is known about ... High level of VEGF expression in skin cancer ...
... Researchers at Purdue University and the National Institute of ... enough to fit on a computer chip that converts ... that might have applications in more advanced sensors, communications ... very high rates, corresponding to hundreds of billions of ...
Cached Biology Technology:
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: